Back Again to the Future: A New Era for Cerebroprotection.

IF 7.7 1区医学 Q1 CLINICAL NEUROLOGY

Annals of Neurology Pub Date : 2025-09-26 DOI:10.1002/ana.78041

Patrick Lyden

引用次数: 0

Abstract

In multiple disease areas, neurology has failed to translate promising treatments from positive preclinical studies to successful clinical trial results. Despite this history, we persist in testing new, putative neuroprotectants using the same concepts, approaches, and methods without much modification. Recent novel data and new concepts offer an opportunity to break with past doctrine decisively, and open a new era of different approaches, methods, and strategies for studying future protections for brain injury. Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. ANN NEUROL 2025.

查看原文本刊更多论文

回到未来：脑保护的新时代。

在多个疾病领域，神经学未能将有希望的治疗方法从积极的临床前研究转化为成功的临床试验结果。尽管有这样的历史，我们坚持使用相同的概念，方法和方法测试新的，假定的神经保护剂，而不做太多修改。最近的新数据和新概念提供了一个机会，果断地打破过去的学说，并打开了一个新的时代，不同的方法，方法和策略，研究未来的保护脑损伤。脑保护是设计神经治疗的新框架，除了神经元外，还针对神经胶质细胞和血管细胞。Ann neurol 2025。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Neurology 医学-临床神经学

CiteScore

18.00

自引率

1.80%

发文量

270

审稿时长

3-8 weeks

期刊介绍： Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.